Self funding of phase 2 is a calculated risk in the absense of a satisfactory big pharma deal. Those making sub-standard offers will now have Biota's attention! A successfull phase 2 will up the value by many many times the phase 2 cost and increase the number of competing offers. Perhaps the chance of success is calculated to be very high.
hrv trial, page-12
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)